Lyell Immunopharma Ratios (2019-2025) | LYEL

Ratios Dec2019 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
EBT Margin -2,441.32%-3,340.84%-1,682.66%-2,250.14%-2,377.82%-1,774.63%-1,673.10%-12,328.93%-101.59%-2,139,533.33%-23.42%-89,321.54%-224,596.30%-209,724.00%-403,261.54%-1,625,200.00%-347,415.38%-131,000.00%-1,783,881.82%-764,357.14%-548,300.00%-226,580.00%
EBIT Margin -2,627.71%-3,443.27%-1,709.52%-2,264.62%-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%
EBITDA Margin -2,277.71%-3,394.11%-1,695.24%-2,255.05%-2,385.27%-1,779.06%-3,021.40%-13,222.60%-106.53%-2,396,633.33%-12.40%-97,290.77%-231,074.07%-198,620.00%-398,792.31%-2,032,566.67%-352,323.08%-127,723.53%-1,749,127.27%-747,542.86%-534,812.50%-258,013.33%
Operating Margin -2,627.71%-3,443.27%-1,709.52%-2,264.62%-2,386.11%-1,784.43%-1,684.55%-12,400.72%-104.25%-2,214,566.67%-30.55%-96,240.00%-244,092.59%-236,156.00%-457,753.85%-1,852,500.00%-396,369.23%-148,544.12%-1,828,609.09%-819,528.57%-589,250.00%-248,353.33%
Net Margin -2,441.32%-3,340.84%-1,682.66%-2,250.14%-2,377.82%-1,774.63%-1,673.10%-12,328.93%-101.59%-2,139,533.33%-23.42%-89,321.54%-224,596.30%-209,724.00%-403,261.54%-1,625,200.00%-347,415.38%-131,000.00%-1,783,881.82%-764,357.14%-548,300.00%-226,580.00%
FCF Margin -3,202.71%-2,232.40%-2,158.98%-2,221.99%-1,346.32%-1,540.79%-10,413.20%-144.10%-1,329,800.00%-92.69%-73,453.85%-148,496.30%-151,524.00%-312,769.23%-1,407,866.67%-294,115.38%-103,238.24%-429,872.73%-785,485.71%-432,825.00%-190,926.67%
Efficiency
Assets Average 1,214.10M1,162.87M1,099.75M1,046.89M999.47M957.41M909.01M857.90M815.17M772.51M722.12M674.18M636.68M555.04M460.33M407.63M396.71M
Equity Average -175.61M-253.38M-279.59M-313.29M343.95M1,004.21M958.13M905.52M874.65M844.03M826.64M808.54M760.34M717.21M676.26M629.05M584.83M548.60M456.76M359.67M317.72M314.02M
Invested Capital -111.11M-240.11M-266.64M-292.53M-334.05M1,021.96M986.47M929.79M881.25M868.04M820.03M833.25M783.83M736.86M697.57M654.95M603.16M566.50M530.70M382.82M336.52M298.92M329.12M
Asset Utilization Ratio 0.010.010.010.040.040.090.090.060.060.000.000.000.000.000.000.000.00
Leverage & Solvency
Equity Ratio -0.320.830.820.820.820.850.840.890.890.880.880.870.870.870.860.780.780.780.81
Valuation
Enterprise Value -96.67M-246.42M-134.88M-612.62M-244.37M2,594.08M2,924.17M1,246.46M625.30M949.24M1,168.43M225.01M-23.69M198.01M-206.42M175.41M40.33M-130.15M-87.26M-191.83M-142.34M-146.25M-7.63M
Market Capitalization 3,418.61M3,543.09M1,861.25M1,239.21M1,604.80M1,816.56M865.16M589.08M793.76M369.01M721.63M566.63M360.96M353.28M178.70M158.83M130.54M311.99M
Return Ratios
Return on Sales -22.64%-22.73%-20.25%-20.06%-25.89%-4.79%-5.52%-2.13%-2.02%-4.01%-3.76%
Return on Capital Employed -0.18%-0.19%-0.22%-0.20%-0.23%-0.20%-0.21%-0.25%-0.26%-0.33%-0.35%-0.35%-0.36%-0.72%-0.86%-0.96%-0.94%
Return on Assets -0.17%-0.18%-0.21%-0.19%-0.22%-0.19%-0.19%-0.23%-0.22%-0.29%-0.30%-0.29%-0.30%-0.60%-0.74%-0.83%-0.83%
Return on Equity 0.51%-0.56%-0.20%-0.22%-0.25%-0.23%-0.26%-0.22%-0.21%-0.26%-0.25%-0.33%-0.34%-0.34%-0.35%-0.73%-0.94%-1.06%-1.04%